Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)

ADAPT Research Group, ADAPT Research Group

Abstract

Objectives: The Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) was designed to evaluate the conventional NSAID naproxen sodium and the selective COX-2 inhibitor celecoxib for primary prevention of Alzheimer's dementia (AD). On 17 December 2004, after the Adenoma Prevention with Celecoxib (APC) trial reported increased cardiovascular risks with celecoxib, the ADAPT Steering Committee suspended treatment and enrollment. This paper reports on cardiovascular and cerebrovascular events in ADAPT.

Design: ADAPT is a randomized, placebo-controlled, parallel chemoprevention trial with 1-46 mo of follow-up.

Setting: The trial was conducted at six field sites in the United States: Baltimore, Maryland; Boston, Massachusetts; Rochester, New York; Seattle, Washington; Sun City, Arizona; and Tampa, Florida.

Participants: The 2,528 participants were aged 70 y and older with a family history of AD.

Interventions: Study treatments were celecoxib (200 mg b.i.d.), naproxen sodium (220 mg b.i.d.), and placebo.

Outcome measures: Outcome measures were deaths, along with nonfatal myocardial infarction (MI), stroke, congestive heart failure (CHF), transient ischemic attack (TIA), and antihypertensive treatment recorded from structured interviews at scheduled intervals. Cox proportional hazards regression was used to analyze these events individually and in several composites.

Results: Counts (with 3-y incidence) of participants who experienced cardiovascular or cerebrovascular death, MI, stroke, CHF, or TIA in the celecoxib-, naproxen-, and placebo-treated groups were 28/717 (5.54%), 40/713 (8.25%), and 37/1070 (5.68%), respectively. This yielded a hazard ratio (95% confidence interval [CI]) for celecoxib of 1.10 (0.67-1.79) and for naproxen of 1.63 (1.04-2.55). Antihypertensive treatment was initiated in 160/440 (47.43%), 147/427 (45.00%), and 164/644 (34.08%). This yielded hazard ratios (CIs) of 1.56 for celecoxib (1.26-1.94) and 1.40 for naproxen (1.12-1.75).

Conclusions: For celecoxib, ADAPT data do not show the same level of risk as those of the APC trial. The data for naproxen, although not definitive, are suggestive of increased cardiovascular and cerebrovascular risk.

Conflict of interest statement

Competing Interests: See section at end of manuscript.

Figures

Figure 1. Participant Flow Diagram
Figure 1. Participant Flow Diagram
Figure 2. Graph of Time to Cardiovascular…
Figure 2. Graph of Time to Cardiovascular Death, MI, Stroke, CHF, or TIA

References

    1. Szekely CA, Thorne JE, Zandi PP, Ek M, Messias E, et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: A systematic review. Neuroepidemiology. 2004;23:159–169.
    1. Steering Committee of the Alzheimer's Disease Anti-inflammatory Prevention Trial. Statement from the Steering Committee of the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) for communication to the FDA Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee, 18 February 2005. 2005. Available at . Accessed 22 December 2005.
    1. Martin BK, Meinert CL, Breitner JCS, for the ADAPT Research Group Double placebo design in a prevention trial for Alzheimer's disease. Control Clin Trials. 2002;23:93–99.
    1. Shih JH. Sample size calculation for complex clinical trials with survival endpoints. Control Clin Trials. 1995;16:395–407.
    1. Solomon SD, McMurray JV, Pfeffer MA, Wittes J, Fowler R, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071–1080.
    1. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J. 1988;296:320–331.
    1. Bombardier C, Laine L, Reicin A, Shapiro D, Ruben Burgos-Vargas R, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N Engl J Med. 2000;343:1520–1528.
    1. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. JAMA. 2002;284:1247–1255.
    1. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet. 2003;361:573–574.
    1. Kurth T, Glynn RJ, Walker AM, Chan A, Buring JE, et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal anti-inflammatory drugs. Circulation. 2003;108:1191–1195.
    1. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345:433–442.
    1. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954–959.
    1. White WB, Faich G, Borer JS, Makuch RW. Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol. 2003;92:411–418.
    1. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study. Lancet. 2005;365:475–481.
    1. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092–1102.
    1. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005;352:1081–1091.
    1. FitzGerald GA. Coxibs and cardiovascular disease. N Engl J Med. 2004;351:1709–1711.
    1. Davies NM, Jamali F. COX-2 selective inhibitors cardiac toxicity: Getting to the heart of the matter. J Pharm Pharmaceut Sci. 2004;7:332–336.
    1. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006;355:885–895.
    1. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomized trials. BMJ. 2006;332:1302–1308.
    1. Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, et al. Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis. Lancet. 2004;364:2021–2029.
    1. Graham DJ. Testimony of David J. Graham, MD, MPH, 17 February 2005, before the U.S. Food and Drug Administration Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee. 2005. Available at . Accessed 28 July 28 2005.
    1. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med. 2002;162:1111–1115.
    1. Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med. 2002;162:1105–1110.
    1. Solomon DH, Glynn RJ, Levin R, Avorn J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med. 2002;162:1099–1104.
    1. Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006;113:2906–2913.
    1. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal antiinflammatory drugs: Population based nested case-control analysis. BMJ. 2005;330:1366.
    1. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, et al. Effects of rofecoxib or naproxen vs. placebo on Alzheimer disease progression: A randomized controlled trial. JAMA. 2003;289:2819–2826.
    1. Collantes E, Curtis SP, Lee KW, Casas N, McCarthy T, et al. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. BMC Fam Pract. 2002;3:10.
    1. Geusens P, Alten R, Rovensky J, Sloan VS, Krammer G, et al. Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis. Int J Clin Pract. 2004;58:1033–1041.
    1. Hawk E. PPT#964,20: Long-term NSAID use may increase risks of cardiovascular death: A Norwegian study. Slides presented 16 February 2005 at the joint meeting of the U.S. Food and Drug Administration Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee. 2005. Available at . Accessed 28 July 2005.
    1. Packer M. Testimony of Milton Packer, MD, 18 February 2005, before the U.S. Food and Drug Administration Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee. 2005. Available at . Accessed 20 April 2006.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner